Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient.

Literature DB >> 17712837

Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient.

Maria Esteve, Carme Loras, Ferran González-Huix.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17712837 DOI： 10.1002/ibd.20202

Source DB: PubMed Journal: Inflamm Bowel Dis ISSN： 1078-0998 Impact factor: 5.325

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

Review 1. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors: Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal: World J Hepatol Date: 2015-03-27

2. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.

Authors: Ohad Etzion; Victor Novack; Yael Perl; Olga Abel; Doron Schwartz; Daniella Munteanu; Naim Abufreha; Gil Ben-Yaakov; Eyal D Maoz; Alex Moshaklo; Vitaly Dizingf; Alex Fich
Journal: J Crohns Colitis Date: 2016-02-29 Impact factor: 9.071

Review 3. Preventing infective complications in inflammatory bowel disease.

Authors: Justine Mill; Ian C Lawrance
Journal: World J Gastroenterol Date: 2014-08-07 Impact factor: 5.742

4. Hepatitis B vaccination in patients with inflammatory bowel disease.

Authors: Ruwaida Ben Musa; Anuhya Gampa; Sanjib Basu; Ali Keshavarzian; Garth Swanson; Michael Brown; Rana Abraham; Keith Bruninga; John Losurdo; Mark DeMeo; Sohrab Mobarhan; David Shapiro; Ece Mutlu
Journal: World J Gastroenterol Date: 2014-11-07 Impact factor: 5.742

5. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.

Authors: Rajesh Shah; Edith Y Ho; Jennifer R Kramer; Peter Richardson; Shubhada Sansgiry; Hashem B El-Serag; Jason K Hou
Journal: Dig Dis Sci Date: 2018-04-16 Impact factor: 3.199

Review 6. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors: Matthew B Carroll; Michael A Forgione
Journal: Clin Rheumatol Date: 2010-06-16 Impact factor: 2.980

Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient.

Review 1. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

2. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.

Review 3. Preventing infective complications in inflammatory bowel disease.

4. Hepatitis B vaccination in patients with inflammatory bowel disease.

5. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.

Review 6. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Review 7. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

8. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.

Review 9. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.

Review 10. Prevention of Hepatitis B reactivation in the setting of immunosuppression.